Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 52 (10), 815-31

Drug-drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors

Affiliations
Review

Drug-drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors

Benoit Chauvin et al. Clin Pharmacokinet.

Abstract

The HMG-CoA reductase inhibitors are a class of drugs also known as statins. These drugs are effective and widely prescribed for the treatment of hypercholesterolemia and prevention of cardiovascular morbidity and mortality. Seven statins are currently available: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin. Although these drugs are generally well tolerated, skeletal muscle abnormalities from myalgia to severe lethal rhabdomyolysis can occur. Factors that increase statin concentrations such as drug-drug interactions can increase the risk of these adverse events. Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and atorvastatin are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this CYP. All statins are substrate of organic anion transporter polypeptide 1B1, an uptake transporter expressed in hepatocyte membrane that may also explain some drug-drug interactions. Many HIV-infected patients have dyslipidemia and comorbidities that may require statin treatment. HIV-protease inhibitors (HIV PIs) are part of recommended antiretroviral treatment in combination with two reverse transcriptase inhibitors. All HIV PIs except nelfinavir are coadministered with a low dose of ritonavir, a potent CYP3A inhibitor to improve their pharmacokinetic properties. Cobicistat is a new potent CYP3A inhibitor that is combined with elvitegravir and will be combined with HIV-PIs in the future. The HCV-PIs boceprevir and telaprevir are both, to different extents, inhibitors of CYP3A. This review summarizes the pharmacokinetic properties of statins and PIs with emphasis on their metabolic pathways explaining clinically important drug-drug interactions. Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated. Atorvastatin is also a CYP3A substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors. Non-CYP3A-dependent statin concentrations are also affected although to a lesser extent when coadministered with HIV or HCV PIs, mainly through interaction with OATP1B1, and treatment should start with the lowest available statin dose. Effectiveness and occurrence of adverse effects should be monitored at regular time intervals.

Similar articles

See all similar articles

Cited by 30 articles

See all "Cited by" articles

References

    1. J Am Soc Nephrol. 2004 Sep;15(9):2502-3 - PubMed

References

    1. J Cardiovasc Pharmacol. 2008 Jun;51(6):605-10 - PubMed

References

    1. Lancet. 2003 Apr 5;361(9364):1149-58 - PubMed

References

    1. Drug Metab Dispos. 2012 May;40(5):1007-17 - PubMed

References

    1. Clin Pharmacol Ther. 2003 Jun;73(6):554-65 - PubMed

References

    1. Adv Lipid Res. 1976;14:1-74 - PubMed

References

    1. Circulation. 2002 Dec 17;106(25):3143-421 - PubMed

References

    1. N Engl J Med. 2007 Apr 26;356(17):1723-35 - PubMed

References

    1. Adv Drug Deliv Rev. 1999 Oct 18;39(1-3):211-238 - PubMed

References

    1. Annu Rev Pharmacol Toxicol. 2005;45:89-118 - PubMed

References

    1. N Engl J Med. 1998 Nov 5;339(19):1349-57 - PubMed

References

    1. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):457-81 - PubMed

References

    1. J Clin Pharm Ther. 2010 Apr;35(2):139-51 - PubMed

References

    1. Clin Pharmacokinet. 2002;41(5):343-70 - PubMed

References

    1. Lancet. 1998 Jun 20;351(9119):1881-3 - PubMed

References

    1. Eur J Clin Pharmacol. 2001 Aug;57(5):357-64 - PubMed

References

    1. J Clin Pharmacol. 2012 Nov;52(11):1725-38 - PubMed

References

    1. J Antimicrob Chemother. 2004 Jan;53(1):10-4 - PubMed

References

    1. Circulation. 2004 Jul 13;110(2):227-39 - PubMed

References

    1. Trends Pharmacol Sci. 1998 Jan;19(1):26-37 - PubMed

References

    1. Clin Pharmacokinet. 2008;47(7):463-74 - PubMed

References

    1. AIDS. 2010 Jan 2;24(1):77-83 - PubMed

References

    1. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7 - PubMed

References

    1. Expert Rev Clin Pharmacol. 2011 Nov;4(6):729-42 - PubMed

References

    1. Antimicrob Agents Chemother. 2001 Dec;45(12):3445-50 - PubMed

References

    1. Ann Hepatol. 2012 Mar-Apr;11(2):179-85 - PubMed

References

    1. Antiviral Res. 2007 Dec;76(3):203-21 - PubMed

References

    1. Drug Metab Dispos. 2002 May;30(5):505-12 - PubMed

References

    1. N Engl J Med. 2008 Aug 21;359(8):789-99 - PubMed

References

    1. N Engl J Med. 1998 Mar 26;338(13):853-60 - PubMed

References

    1. Antimicrob Agents Chemother. 2011 Oct;55(10):4569-74 - PubMed

References

    1. J Hepatol. 2013 Apr;58(4):792-800 - PubMed

References

    1. N Engl J Med. 2008 Nov 20;359(21):2195-207 - PubMed

References

    1. Int J Clin Pract. 2005 Feb;59(2):239-52 - PubMed

References

    1. Eur J Intern Med. 2012 Jun;23(4):317-24 - PubMed

References

    1. Pharmacotherapy. 2009 Jul;29(7):800-11 - PubMed

References

    1. N Engl J Med. 1996 Oct 3;335(14):1001-9 - PubMed

References

    1. Clin Infect Dis. 2003 Sep 1;37(5):613-27 - PubMed

References

    1. N Engl J Med. 1995 Dec 7;333(23):1528-33 - PubMed

References

    1. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85 - PubMed

References

    1. Antivir Ther. 2011;16(8):1187-201 - PubMed

References

    1. Pharmacoepidemiol Drug Saf. 2004 Jul;13(7):417-26 - PubMed

References

    1. Curr Atheroscler Rep. 2003 Sep;5(5):372-8 - PubMed

References

    1. Int J Cardiol. 1997 Dec 31;62 Suppl 2:S23-9 - PubMed

References

    1. Am J Cardiol. 2006 Apr 17;97(8A):77C-81C - PubMed

References

    1. Gastroenterology. 2006 May;130(6):1793-806 - PubMed

References

    1. Circulation. 2006 Dec 19;114(25):2788-97 - PubMed

References

    1. Antimicrob Agents Chemother. 2009 Oct;53(10):4385-92 - PubMed

References

    1. J Am Board Fam Med. 2007 Jul-Aug;20(4):411-6 - PubMed

References

    1. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1184-95 - PubMed

References

    1. Antivir Ther. 2011;16(3):435-7 - PubMed

References

    1. N Engl J Med. 2006 Aug 10;355(6):549-59 - PubMed

References

    1. Clin Ther. 2007 Aug;29(8):1761-70 - PubMed

References

    1. Int J Nephrol. 2012;2012:806872 - PubMed

References

    1. Pharmacol Ther. 2006 Oct;112(1):71-105 - PubMed

References

    1. Clin Ther. 2000 May;22(5):549-72 - PubMed

References

    1. Expert Opin Drug Saf. 2012 Nov;11(6):933-46 - PubMed

References

    1. Clin Pharmacokinet. 2001;40(4):263-81 - PubMed

References

    1. Clin Pharmacokinet. 2003;42(13):1141-60 - PubMed

References

    1. AIDS Patient Care STDS. 2003 May;17(5):207-10 - PubMed

References

    1. Expert Opin Pharmacother. 2007 Oct;8(14):2315-27 - PubMed

References

    1. Ann Pharmacother. 2001 Sep;35(9):1096-107 - PubMed

References

    1. Lancet. 1998 Nov 28;352(9142):1725-30 - PubMed

References

    1. Atherosclerosis. 2011 Mar;215(1):1-8 - PubMed

References

    1. Mol Pharmacol. 2005 Oct;68(4):1031-8 - PubMed

References

    1. Hepatology. 2011 Oct;54(4):1433-44 - PubMed

References

    1. Pharmacol Rev. 2011 Mar;63(1):157-81 - PubMed

References

    1. Drugs Aging. 2007;24(5):429-40 - PubMed

References

    1. Clin Pharmacokinet. 1997 May;32(5):403-25 - PubMed

References

    1. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):703-29 - PubMed

References

    1. Infect Genet Evol. 2007 Mar;7(2):333-42 - PubMed

References

    1. Pharmacogenomics. 2009 Oct;10(10):1617-24 - PubMed

References

    1. Diabetes Care. 2009 Oct;32(10):1924-9 - PubMed

References

    1. Am J Health Syst Pharm. 2002 Apr 15;59(8):728-30 - PubMed

References

    1. N Engl J Med. 1990 Jun 7;322(23):1635-41 - PubMed

References

    1. Lancet. 2010 Feb 27;375(9716):735-42 - PubMed

References

    1. JAMA. 2012 Jul 25;308(4):387-402 - PubMed

References

    1. Pharmacogenomics J. 2010 Feb;10(1):1-11 - PubMed

References

    1. Clin Pharmacokinet. 2002;41(14):1195-211 - PubMed

References

    1. Lancet. 1994 Nov 19;344(8934):1383-9 - PubMed

References

    1. Ann Pharmacother. 2012 Dec;46(12):1671-7 - PubMed

References

    1. Drug Metab Dispos. 2007 May;35(5):779-86 - PubMed

References

    1. Antiviral Res. 2010 Jan;85(1):190-200 - PubMed

References

    1. AIDS. 2006 Mar 21;20(5):725-9 - PubMed

References

    1. J Viral Hepat. 2012 May;19 Suppl 2:1-26 - PubMed

References

    1. Expert Opin Pharmacother. 2012 Nov;13(16):2301-17 - PubMed

References

    1. J Am Acad Nurse Pract. 2005 Apr;17(4):123-32 - PubMed

References

    1. Pharm Res. 2004 Sep;21(9):1686-91 - PubMed

References

    1. Lancet. 2002 Jul 6;360(9326):7-22 - PubMed

References

    1. J Clin Pharmacol. 1992 Jul;32(7):630-8 - PubMed

References

    1. AIDS. 2003 Nov 21;17(17):2479-86 - PubMed

References

    1. Clin Pharmacol Ther. 2006 Dec;80(6):565-81 - PubMed

References

    1. Trends Pharmacol Sci. 2010 Jan;31(1):22-35 - PubMed

References

    1. Clin Pharmacol Ther. 2005 Dec;78(6):605-18 - PubMed

References

    1. Drug Saf. 2008;31(12):1115-23 - PubMed

References

    1. FEBS Lett. 1976 Dec 31;72(2):323-6 - PubMed

References

    1. Pharmacotherapy. 2013 Oct;33(10):1107-16 - PubMed

References

    1. Antivir Ther. 2007;12(7):1127-32 - PubMed

References

    1. AIDS. 2012 Sep 10;26(14):1801-5 - PubMed

References

    1. Clin Pharmacol Ther. 2012 Nov;92(5):584-98 - PubMed

References

    1. Curr Med Res Opin. 2009 Nov;25(11):2755-64 - PubMed

References

    1. Dig Liver Dis. 2006 Jun;38(6):363-73 - PubMed

References

    1. Am J Cardiol. 2003 Aug 1;92(3):270-4 - PubMed

References

    1. Clin Pharmacol Ther. 2006 Oct;80(4):356-66 - PubMed

References

    1. Clin Pharmacol Ther. 2010 Mar;87(3):322-9 - PubMed

References

    1. Nature. 1990 Feb 1;343(6257):425-30 - PubMed

References

    1. JAMA. 2001 May 16;285(19):2486-97 - PubMed

References

    1. Pharmacol Ther. 2011 Dec;132(3):268-79 - PubMed

References

    1. Clin Infect Dis. 2002 Nov 15;35(10):e111-2 - PubMed

References

    1. J Clin Endocrinol Metab. 1992 May;74(5):1045-52 - PubMed

References

    1. Lancet. 1999 Jun 19;353(9170):2093-9 - PubMed

References

    1. AIDS. 2002 Mar 8;16(4):569-77 - PubMed

References

    1. N Engl J Med. 1995 Nov 16;333(20):1301-7 - PubMed

References

    1. J Infect Dis. 2013 Jul;208(1):32-9 - PubMed

References

    1. Clin Ther. 2007 Nov;29(11):2365-73 - PubMed

References

    1. N Engl J Med. 2002 Feb 14;346(7):539-40 - PubMed

References

    1. Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14 - PubMed

References

    1. Int J Antimicrob Agents. 2003 Jul;22(1):54-9 - PubMed

References

    1. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):570-8 - PubMed

References

    1. Am J Nephrol. 2011;34(3):195-202 - PubMed

References

    1. BMJ. 2008 Nov 06;337:a2286 - PubMed

References

    1. J Hepatol. 2011 Aug;55(2):245-64 - PubMed

References

    1. Clin Ther. 1997 Mar-Apr;19(2):187-214 - PubMed

References

    1. J Antimicrob Chemother. 2008 Feb;61(2):238-45 - PubMed

References

    1. Liver Int. 2013 Feb;33 Suppl 1:30-4 - PubMed

References

    1. Clin Pharmacol Ther. 2009 Aug;86(2):197-203 - PubMed

References

    1. Drug Saf. 2000 Jun;22(6):441-57 - PubMed

References

    1. Pharm Res. 2007 Feb;24(2):239-47 - PubMed

References

    1. Pharmacotherapy. 2000 Sep;20(9):1066-71 - PubMed

References

    1. Circulation. 2001 Jul 17;104(3):257-62 - PubMed

References

    1. JAMA. 1998 May 27;279(20):1615-22 - PubMed

References

    1. Clin Pharmacokinet. 2011 Apr;50(4):229-44 - PubMed

References

    1. Curr Opin Investig Drugs. 2010 Mar;11(3):323-32 - PubMed

References

    1. Pharmacol Ther. 1999 Dec;84(3):413-28 - PubMed

References

    1. Clin Ther. 2003 Oct;25(10):2553-63 - PubMed

MeSH terms

Substances

Feedback